Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Interchange of vaccine products, Nasal discharge discolouration, Upper-airway cough syndrome
Clinical narrative: Postnasal drip; White discharge from sinus; Slight cough; dose 1 brand: Moderna/dose 2 brand: Moderna/ dose 3 brand: Moderna booster/dose brand: Pfizer; Headache; Redness; Soreness and fever in shoulder; Soreness and fever in shoulder; This is a spontaneous report received from a contactable reporter (Consumer or other non HCP). The reporter is the patient.  A 67-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 20Sep2022 at 16:00 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 67 years, in left arm for covid-19 immunization. Patient received first dose of Fluid 65 at Left shoulder on 20Sep2022. The patient's relevant medical history included: "Type 2 diabetic" (unspecified if ongoing), notes: Type 2 diabetic; "High cholesterol" (unspecified if ongoing); "Rapid heartbeat" (unspecified if ongoing), notes: Rapid heartbeat; "Fibromyalgia" (unspecified if ongoing). Concomitant medication(s) included: XIGDUO; ATORVASTATIN; CYMBALTA; ASPIRIN [ACETYLSALICYLIC ACID]; METOPROLOL. Vaccination history included: moderna coviD-19 vaccine (DOSE 3 (BOOSTER), SINGLE, Arm Left), administration date: 05Nov2021, when the patient was 66-year-old, for COVID-19 immunization; moderna coviD-19 vaccine (DOSE 2, SINGLE, Arm Left), administration date: 06Mar2021, when the patient was 66-year-old, for COVID-19 immunization; moderna coviD-19 vaccine (DOSE 1, SINGLE, Arm Left), administration date: 11Feb2021, when the patient was 66-year-old, for COVID-19 immunization. The following information was reported: HEADACHE (non-serious) with onset 20Sep2022 at 16:00, outcome "recovering"; ERYTHEMA (non-serious) with onset 20Sep2022 at 16:00, outcome "recovering", described as "Redness"; COUGH (non-serious) with onset 20Sep2022 at 16:00, outcome "recovering", described as "Slight cough"; ARTHRALGIA (non-serious), FEELING HOT (non-serious) all with onset 20Sep2022 at 16:00, outcome "recovering" and all described as "Soreness and fever in shoulder"; INTERCHANGE OF VACCINE PRODUCTS (non-serious) with onset 20Sep2022 at 16:00, outcome "unknown", described as "dose 1 brand: Moderna/dose 2 brand: Moderna/ dose 3 brand: Moderna booster/dose brand: Pfizer"; NASAL DISCHARGE DISCOLOURATION (non-serious) with onset 22Sep2022, outcome "recovering", described as "White discharge from sinus"; UPPER-AIRWAY COUGH SYNDROME (non-serious) with onset 23Sep2022, outcome "recovering", described as "Postnasal drip". Therapeutic measures were not taken as a result of headache, erythema, arthralgia, feeling hot, cough, upper-airway cough syndrome. Therapeutic measures were taken as a result of nasal discharge discolouration.   Additional information: Days 1 & 2 headache, redness, soreness and fever in shoulder. Day 3 white discharge from sinus. Day 4 postnasal drip. Flushed out sinuses with saline spray. Will continue to flush sinuses each day. Slight cough. No COVID prior vaccination. COVID was not tested post vaccination. No known allergies.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.